instruction
stringlengths 39
316
| response
stringlengths 121
336
| text
stringlengths 194
685
|
|---|---|---|
Could you tell me the median Progression-Free Survival rate for patients who received Ciltacabtagene Autoleucel (Cilta-Cel) regimen? | Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Ciltacabtagene Autoleucel (Cilta-Cel) regimen?
### Response: Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). |
What’s the median rate of PFS in patients treated with Ciltacabtagene Autoleucel (Cilta-Cel) regimen? | Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). | ### Instruction: What’s the median rate of PFS in patients treated with Ciltacabtagene Autoleucel (Cilta-Cel) regimen?
### Response: Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). |
Can you share the median Progression-Free Survival rate in patients who have received Ciltacabtagene Autoleucel (Cilta-Cel) regimen? | Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Ciltacabtagene Autoleucel (Cilta-Cel) regimen?
### Response: Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). |
Can you tell me the median PFS for Cilta-Cel? | Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: Can you tell me the median PFS for Cilta-Cel?
### Response: Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
What’s the median PFS associated with Cilta-Cel? | Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: What’s the median PFS associated with Cilta-Cel?
### Response: Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
Could you provide the median PFS of Cilta-Cel? | Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: Could you provide the median PFS of Cilta-Cel?
### Response: Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
I’d like to know the median PFS of Cilta-Cel. | Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: I’d like to know the median PFS of Cilta-Cel.
### Response: Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
Do you have information on the median PFS of Cilta-Cel? | Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: Do you have information on the median PFS of Cilta-Cel?
### Response: Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
What is the median progression-free survival (PFS) for Cilta-Cel? | Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: What is the median progression-free survival (PFS) for Cilta-Cel?
### Response: Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
Can you inform me about the median PFS for Cilta-Cel? | Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: Can you inform me about the median PFS for Cilta-Cel?
### Response: Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
I’m interested in the median PFS of Cilta-Cel. | Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: I’m interested in the median PFS of Cilta-Cel.
### Response: Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
Could you tell me the median PFS for Cilta-Cel? | Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: Could you tell me the median PFS for Cilta-Cel?
### Response: Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
What is the median PFS rate for Cilta-Cel? | Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: What is the median PFS rate for Cilta-Cel?
### Response: Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
What is the median Progression-Free Survival (PFS) rate in patients treated with Cilta-Cel regimen? | Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Cilta-Cel regimen?
### Response: Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
What is the median PFS rate in patients who have undergone Cilta-Cel regimen? | Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: What is the median PFS rate in patients who have undergone Cilta-Cel regimen?
### Response: Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Cilta-Cel regimen? | Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Cilta-Cel regimen?
### Response: Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
What’s the median PFS rate for patients receiving Cilta-Cel regimen? | Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: What’s the median PFS rate for patients receiving Cilta-Cel regimen?
### Response: Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
Could you provide the median Progression-Free Survival rate for patients treated with Cilta-Cel regimen? | Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Cilta-Cel regimen?
### Response: Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
What is the median rate of Progression-Free Survival in patients who have been treated with Cilta-Cel regimen? | Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Cilta-Cel regimen?
### Response: Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
Can you inform me about the median PFS rate in patients that were treated with Cilta-Cel regimen? | Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Cilta-Cel regimen?
### Response: Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
What is the median PFS rate for patients that have undergone Cilta-Cel regimen? | Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: What is the median PFS rate for patients that have undergone Cilta-Cel regimen?
### Response: Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
Could you tell me the median Progression-Free Survival rate for patients who received Cilta-Cel regimen? | Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Cilta-Cel regimen?
### Response: Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
What’s the median rate of PFS in patients treated with Cilta-Cel regimen? | Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: What’s the median rate of PFS in patients treated with Cilta-Cel regimen?
### Response: Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
Can you share the median Progression-Free Survival rate in patients who have received Cilta-Cel regimen? | Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Cilta-Cel regimen?
### Response: Patients treated with the Cilta-Cel have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
Can you tell me the median PFS for Teclistamab? | Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). | ### Instruction: Can you tell me the median PFS for Teclistamab?
### Response: Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). |
What’s the median PFS associated with Teclistamab? | Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). | ### Instruction: What’s the median PFS associated with Teclistamab?
### Response: Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). |
Could you provide the median PFS of Teclistamab? | Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). | ### Instruction: Could you provide the median PFS of Teclistamab?
### Response: Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). |
I’d like to know the median PFS of Teclistamab. | Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). | ### Instruction: I’d like to know the median PFS of Teclistamab.
### Response: Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). |
Do you have information on the median PFS of Teclistamab? | Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). | ### Instruction: Do you have information on the median PFS of Teclistamab?
### Response: Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). |
What is the median progression-free survival (PFS) for Teclistamab? | Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). | ### Instruction: What is the median progression-free survival (PFS) for Teclistamab?
### Response: Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). |
Can you inform me about the median PFS for Teclistamab? | Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). | ### Instruction: Can you inform me about the median PFS for Teclistamab?
### Response: Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). |
I’m interested in the median PFS of Teclistamab. | Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). | ### Instruction: I’m interested in the median PFS of Teclistamab.
### Response: Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). |
Could you tell me the median PFS for Teclistamab? | Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). | ### Instruction: Could you tell me the median PFS for Teclistamab?
### Response: Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). |
What is the median PFS rate for Teclistamab? | Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). | ### Instruction: What is the median PFS rate for Teclistamab?
### Response: Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Teclistamab regimen? | Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Teclistamab regimen?
### Response: Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). |
What is the median PFS rate in patients who have undergone Teclistamab regimen? | Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). | ### Instruction: What is the median PFS rate in patients who have undergone Teclistamab regimen?
### Response: Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Teclistamab regimen? | Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Teclistamab regimen?
### Response: Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). |
What’s the median PFS rate for patients receiving Teclistamab regimen? | Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). | ### Instruction: What’s the median PFS rate for patients receiving Teclistamab regimen?
### Response: Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). |
Could you provide the median Progression-Free Survival rate for patients treated with Teclistamab regimen? | Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Teclistamab regimen?
### Response: Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). |
What is the median rate of Progression-Free Survival in patients who have been treated with Teclistamab regimen? | Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Teclistamab regimen?
### Response: Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). |
Can you inform me about the median PFS rate in patients that were treated with Teclistamab regimen? | Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Teclistamab regimen?
### Response: Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). |
What is the median PFS rate for patients that have undergone Teclistamab regimen? | Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). | ### Instruction: What is the median PFS rate for patients that have undergone Teclistamab regimen?
### Response: Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). |
Could you tell me the median Progression-Free Survival rate for patients who received Teclistamab regimen? | Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Teclistamab regimen?
### Response: Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). |
What’s the median rate of PFS in patients treated with Teclistamab regimen? | Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). | ### Instruction: What’s the median rate of PFS in patients treated with Teclistamab regimen?
### Response: Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). |
Can you share the median Progression-Free Survival rate in patients who have received Teclistamab regimen? | Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Teclistamab regimen?
### Response: Patients treated with the Teclistamab have a median Progression-Free Survival (PFS) rate of 11.3 months, with a 95% CI of (8.8, 17.1). |
Can you tell me the median PFS for CT103A? | Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: Can you tell me the median PFS for CT103A?
### Response: Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
What’s the median PFS associated with CT103A? | Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: What’s the median PFS associated with CT103A?
### Response: Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
Could you provide the median PFS of CT103A? | Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: Could you provide the median PFS of CT103A?
### Response: Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
I’d like to know the median PFS of CT103A. | Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: I’d like to know the median PFS of CT103A.
### Response: Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
Do you have information on the median PFS of CT103A? | Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: Do you have information on the median PFS of CT103A?
### Response: Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
What is the median progression-free survival (PFS) for CT103A? | Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: What is the median progression-free survival (PFS) for CT103A?
### Response: Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
Can you inform me about the median PFS for CT103A? | Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: Can you inform me about the median PFS for CT103A?
### Response: Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
I’m interested in the median PFS of CT103A. | Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: I’m interested in the median PFS of CT103A.
### Response: Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
Could you tell me the median PFS for CT103A? | Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: Could you tell me the median PFS for CT103A?
### Response: Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
What is the median PFS rate for CT103A? | Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: What is the median PFS rate for CT103A?
### Response: Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
What is the median Progression-Free Survival (PFS) rate in patients treated with CT103A regimen? | Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with CT103A regimen?
### Response: Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
What is the median PFS rate in patients who have undergone CT103A regimen? | Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: What is the median PFS rate in patients who have undergone CT103A regimen?
### Response: Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
Can you tell me the median Progression-Free Survival rate in patients who were treated with CT103A regimen? | Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with CT103A regimen?
### Response: Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
What’s the median PFS rate for patients receiving CT103A regimen? | Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: What’s the median PFS rate for patients receiving CT103A regimen?
### Response: Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
Could you provide the median Progression-Free Survival rate for patients treated with CT103A regimen? | Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with CT103A regimen?
### Response: Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
What is the median rate of Progression-Free Survival in patients who have been treated with CT103A regimen? | Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with CT103A regimen?
### Response: Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
Can you inform me about the median PFS rate in patients that were treated with CT103A regimen? | Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with CT103A regimen?
### Response: Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
What is the median PFS rate for patients that have undergone CT103A regimen? | Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: What is the median PFS rate for patients that have undergone CT103A regimen?
### Response: Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
Could you tell me the median Progression-Free Survival rate for patients who received CT103A regimen? | Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received CT103A regimen?
### Response: Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
What’s the median rate of PFS in patients treated with CT103A regimen? | Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: What’s the median rate of PFS in patients treated with CT103A regimen?
### Response: Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
Can you share the median Progression-Free Survival rate in patients who have received CT103A regimen? | Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received CT103A regimen?
### Response: Patients treated with the CT103A have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
Can you tell me the median PFS for Belantamab Mafodotin? | Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. | ### Instruction: Can you tell me the median PFS for Belantamab Mafodotin?
### Response: Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. |
What’s the median PFS associated with Belantamab Mafodotin? | Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. | ### Instruction: What’s the median PFS associated with Belantamab Mafodotin?
### Response: Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. |
Could you provide the median PFS of Belantamab Mafodotin? | Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. | ### Instruction: Could you provide the median PFS of Belantamab Mafodotin?
### Response: Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. |
I’d like to know the median PFS of Belantamab Mafodotin. | Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. | ### Instruction: I’d like to know the median PFS of Belantamab Mafodotin.
### Response: Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. |
Do you have information on the median PFS of Belantamab Mafodotin? | Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. | ### Instruction: Do you have information on the median PFS of Belantamab Mafodotin?
### Response: Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. |
What is the median progression-free survival (PFS) for Belantamab Mafodotin? | Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. | ### Instruction: What is the median progression-free survival (PFS) for Belantamab Mafodotin?
### Response: Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. |
Can you inform me about the median PFS for Belantamab Mafodotin? | Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. | ### Instruction: Can you inform me about the median PFS for Belantamab Mafodotin?
### Response: Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. |
I’m interested in the median PFS of Belantamab Mafodotin. | Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. | ### Instruction: I’m interested in the median PFS of Belantamab Mafodotin.
### Response: Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. |
Could you tell me the median PFS for Belantamab Mafodotin? | Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. | ### Instruction: Could you tell me the median PFS for Belantamab Mafodotin?
### Response: Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. |
What is the median PFS rate for Belantamab Mafodotin? | Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. | ### Instruction: What is the median PFS rate for Belantamab Mafodotin?
### Response: Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. |
What is the median Progression-Free Survival (PFS) rate in patients treated with Belantamab Mafodotin regimen? | Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Belantamab Mafodotin regimen?
### Response: Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. |
What is the median PFS rate in patients who have undergone Belantamab Mafodotin regimen? | Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. | ### Instruction: What is the median PFS rate in patients who have undergone Belantamab Mafodotin regimen?
### Response: Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Belantamab Mafodotin regimen? | Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Belantamab Mafodotin regimen?
### Response: Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. |
What’s the median PFS rate for patients receiving Belantamab Mafodotin regimen? | Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. | ### Instruction: What’s the median PFS rate for patients receiving Belantamab Mafodotin regimen?
### Response: Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. |
Could you provide the median Progression-Free Survival rate for patients treated with Belantamab Mafodotin regimen? | Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Belantamab Mafodotin regimen?
### Response: Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. |
What is the median rate of Progression-Free Survival in patients who have been treated with Belantamab Mafodotin regimen? | Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Belantamab Mafodotin regimen?
### Response: Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. |
Can you inform me about the median PFS rate in patients that were treated with Belantamab Mafodotin regimen? | Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Belantamab Mafodotin regimen?
### Response: Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. |
What is the median PFS rate for patients that have undergone Belantamab Mafodotin regimen? | Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. | ### Instruction: What is the median PFS rate for patients that have undergone Belantamab Mafodotin regimen?
### Response: Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. |
Could you tell me the median Progression-Free Survival rate for patients who received Belantamab Mafodotin regimen? | Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Belantamab Mafodotin regimen?
### Response: Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. |
What’s the median rate of PFS in patients treated with Belantamab Mafodotin regimen? | Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. | ### Instruction: What’s the median rate of PFS in patients treated with Belantamab Mafodotin regimen?
### Response: Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. |
Can you share the median Progression-Free Survival rate in patients who have received Belantamab Mafodotin regimen? | Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Belantamab Mafodotin regimen?
### Response: Patients treated with the Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of None. |
Can you tell me the median PFS for Pomalidomide+Dexamethasone? | Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7 months, with a 95% CI of None. | ### Instruction: Can you tell me the median PFS for Pomalidomide+Dexamethasone?
### Response: Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7 months, with a 95% CI of None. |
What’s the median PFS associated with Pomalidomide+Dexamethasone? | Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7 months, with a 95% CI of None. | ### Instruction: What’s the median PFS associated with Pomalidomide+Dexamethasone?
### Response: Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7 months, with a 95% CI of None. |
Could you provide the median PFS of Pomalidomide+Dexamethasone? | Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7 months, with a 95% CI of None. | ### Instruction: Could you provide the median PFS of Pomalidomide+Dexamethasone?
### Response: Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7 months, with a 95% CI of None. |
I’d like to know the median PFS of Pomalidomide+Dexamethasone. | Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7 months, with a 95% CI of None. | ### Instruction: I’d like to know the median PFS of Pomalidomide+Dexamethasone.
### Response: Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7 months, with a 95% CI of None. |
Do you have information on the median PFS of Pomalidomide+Dexamethasone? | Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7 months, with a 95% CI of None. | ### Instruction: Do you have information on the median PFS of Pomalidomide+Dexamethasone?
### Response: Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7 months, with a 95% CI of None. |
What is the median progression-free survival (PFS) for Pomalidomide+Dexamethasone? | Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7 months, with a 95% CI of None. | ### Instruction: What is the median progression-free survival (PFS) for Pomalidomide+Dexamethasone?
### Response: Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7 months, with a 95% CI of None. |
Can you inform me about the median PFS for Pomalidomide+Dexamethasone? | Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7 months, with a 95% CI of None. | ### Instruction: Can you inform me about the median PFS for Pomalidomide+Dexamethasone?
### Response: Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7 months, with a 95% CI of None. |
I’m interested in the median PFS of Pomalidomide+Dexamethasone. | Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7 months, with a 95% CI of None. | ### Instruction: I’m interested in the median PFS of Pomalidomide+Dexamethasone.
### Response: Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7 months, with a 95% CI of None. |
Could you tell me the median PFS for Pomalidomide+Dexamethasone? | Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7 months, with a 95% CI of None. | ### Instruction: Could you tell me the median PFS for Pomalidomide+Dexamethasone?
### Response: Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7 months, with a 95% CI of None. |
What is the median PFS rate for Pomalidomide+Dexamethasone? | Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7 months, with a 95% CI of None. | ### Instruction: What is the median PFS rate for Pomalidomide+Dexamethasone?
### Response: Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7 months, with a 95% CI of None. |
What is the median Progression-Free Survival (PFS) rate in patients treated with Pomalidomide+Dexamethasone regimen? | Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7 months, with a 95% CI of None. | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Pomalidomide+Dexamethasone regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7 months, with a 95% CI of None. |
What is the median PFS rate in patients who have undergone Pomalidomide+Dexamethasone regimen? | Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7 months, with a 95% CI of None. | ### Instruction: What is the median PFS rate in patients who have undergone Pomalidomide+Dexamethasone regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7 months, with a 95% CI of None. |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Pomalidomide+Dexamethasone regimen? | Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7 months, with a 95% CI of None. | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Pomalidomide+Dexamethasone regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7 months, with a 95% CI of None. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.